Drugs / OCH-NCNP1
OCH-NCNP1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04211740 Comparator | Dec 2019 → May 2023 | relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis | National Center of Neurology and Psychiatry, Japan | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCH-NCNP1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04211740 ↗ |
| Known as | (2S, 3S, 4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonaetriol | “The glycolipid (2S, 3S, 4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonaetriol (OCH-NCNP1 or OCH) exerts an immunoregulatory action” PMID 38224478 ↗ Jan 2024 |
| Known as | OCH | “The glycolipid (2S, 3S, 4R)-1-O-(α-d-galactosyl)-2-tetracosanoylamino-1,3,4-nonaetriol (OCH-NCNP1 or OCH) exerts an immunoregulatory action” PMID 38224478 ↗ Jan 2024 |
| Route | Oral | “the investigational drug (3.0 mg) was orally administered once weekly” PMID 38224478 ↗ Jan 2024 |